Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study

Fig. 1

Hepatitis B virus surface antibody (HBsAb) titers, cumulative person-years (PY), and incidence rates of detectable hepatitis B virus (HBV) DNA and reactivation. CI confidence interval, HBcAb hepatitis B virus core antibody, HBsAg hepatitis B virus surface antigen

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us